Research Article Details
| Article ID: | A10960 |
| PMID: | 31101783 |
| Source: | Georgian Med News |
| Title: | RESULTS OF CORRECTION OF THE HEPATIC STEATOSIS ON THE BACKGROUND OF HYPERTENSION AND OVERWEIGHT WITH HELP OF ESSENTIAL PHOSPHOLIPID COMPLEX. |
| Abstract: | One of the unfavorable factors contributing to the formation of cardiovascular risk in non-alcoholic fatty liver disease (NAFLD) on the background of hypertension is the low level of HDL cholesterol, in the metabolism of which the activity of endothelial lipase (EL) plays a leading role. The liver plays an important role in the formation of dyslipidemia and is a target for lipid metabolism disorders, representing one of the pathogenetic stages of NAFLD formation, which dictates the search for ways of drug "support" of hepatocytes. The aim of the research was to study the effectiveness of essential phospholipids in the complex therapy of patients with NAFLD, hypertension and overweight, taking into account the dynamics of laboratory and instrumental examinations and EL blood level. 52 patients with NAFLD on the background of hypertension and overweight have been examined. The control group consisted of 20 practically healthy people. All patients were divided with accordance of age and sex. Dietary nutrition with reduction of simple carbohydrates and fats was recommended for patients and treatment with essential phospholipids for 6 months at a dose of 2 capsules 3 times a day was prescribed. 16 patients of the main group showed complete compliance till the end of the course of treatment. The concentration of EL was determined by the ELISA using the Aviscera Bioscience INC reagents kit (USA). The complex of essential phospholipids as additional component for diet showed an effective decrease in the severity of hepatic steatosis in combination with the reduction of insulin resistance, as well as the restoration of normal pathogenetic functional links between HDL and endothelial lipase in patients with NAFLD on background of hypertension. Thus essential phospholipids can be recommended to reduce CVD and comorbidity for all patient`s with these diseases, which was mentioned above, despite the range of steatosis. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I12 | 10763 | Hypertension | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D258 | Omega 3 PUFA | Chemical drug | DB11133 | PPARG ligand; PPARA activator | Hypolipidemic drug | Under clinical trials | Details |
| D075 | Choline | Supplement | DB00122 | PLD2 product of; PLD1 product of | -- | Under clinical trials | Details |
| D273 | Phosphatidylcholine | Chemical drug | DB15834 | -- | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D125 | Epanova | Chemical drug | DB11133 | PPARG ligand; PPARA activator | Enhance lipid metabolism | Under clinical trials | Details |